Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Work In Process (2016 - 2017)

Vanda Pharmaceuticals' Work In Process history spans 4 years, with the latest figure at $80000.0 for Q4 2017.

  • On a quarterly basis, Work In Process rose 370.59% to $80000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $80000.0, a 370.59% increase, with the full-year FY2017 number at $80000.0, up 370.59% from a year prior.
  • Work In Process hit $80000.0 in Q4 2017 for Vanda Pharmaceuticals, up from $63000.0 in the prior quarter.
  • Over the last five years, Work In Process for VNDA hit a ceiling of $1.8 million in Q2 2015 and a floor of $7000.0 in Q2 2014.
  • Historically, Work In Process has averaged $564833.3 across 4 years, with a median of $71500.0 in 2017.
  • Biggest five-year swings in Work In Process: surged 25300.0% in 2015 and later soared 370.59% in 2017.
  • Tracing VNDA's Work In Process over 4 years: stood at $1.3 million in 2014, then increased by 19.0% to $1.6 million in 2015, then plummeted by 98.92% to $17000.0 in 2016, then soared by 370.59% to $80000.0 in 2017.
  • Business Quant data shows Work In Process for VNDA at $80000.0 in Q4 2017, $63000.0 in Q3 2017, and $131000.0 in Q2 2017.